Yajie Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yajie Chen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Dakui Luo
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
7 shared publications - Di Zhou
Affiliation Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 shared publications - Fan Xia
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
7 shared publications - Fangqi Liu
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center
7 shared publications - Hui Zhang
Shanghai Research Center for Theoretical Nuclear Physics NSFC and Fudan University 200438 Shanghai China
7 shared publications - Jinluan Li
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
7 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Duration of cCR in each individual patient who adopted WW
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Duration of cCR in each individual patient who adopted WW
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Characteristics of Patients Developing Tumor Recurrence
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Characteristics of Patients Developing Tumor Recurrence
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Postoperative complications according to Clavien- Dindo classification
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Postoperative complications according to Clavien- Dindo classification
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Representativeness of Study Participants
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Representativeness of Study Participants
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 4976-4984
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Purpose: Organ preservation (OP) can be preferred in low-lying rectal cancer to reduce morbidity from radical surgery. Immunotherapy-based total neoadjuvant therapy (iTNT) showed remarkable tumor regression and facilitated OP in locally advanced rectal cancer. This study evaluated the efficacy and safety of iTNT, comprising short-course radiotherapy followed by CAPOX and toripalimab, in enabling OP for early low rectal cancer. Patients and Methods: TORCH-E was a multicenter, single-arm phase II trial enrolling patients with T2–3bN0 rectal adenocarcinoma ≤5 cm from the anal verge. Patients received short-course radiotherapy (25 Gy/5 Fx) followed by four cycles of CAPOX plus toripalimab. Good responders were eligible for watch-and-wait (WW) or local excision (LE), and total mesorectal excision was recommended for poor responders or those with high-risk features after LE. The primary endpoint was complete response (CR), including clinical CR with WW and pathologic CR. Secondary endpoints included OP rate, adverse effects, and quality of life. Results: From December 2022 to March 2024, 33 patients were enrolled, with 75.8% staged as T3. After iTNT, 16 patients achieved clinical CR and adopted WW. Pathologic CR was observed in eight of eight LE and five of nine patients who underwent total mesorectal excision. The most common grade 3 to 4 adverse event was thrombocytopenia (27.3%). After a median follow-up of 24.1 months, four local regrowths and one metastatic recurrence occurred. The total CR rate was 72.7%, and the OP rate was 60.6%. Conclusions: As an exploratory trial, TORCH-E demonstrated a promising iTNT approach achieving a high CR rate, enabling OP through WW and selective LE in early low rectal cancer, warranting subsequent randomized validation.
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 4976-4984
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Purpose: Organ preservation (OP) can be preferred in low-lying rectal cancer to reduce morbidity from radical surgery. Immunotherapy-based total neoadjuvant therapy (iTNT) showed remarkable tumor regression and facilitated OP in locally advanced rectal cancer. This study evaluated the efficacy and safety of iTNT, comprising short-course radiotherapy followed by CAPOX and toripalimab, in enabling OP for early low rectal cancer. Patients and Methods: TORCH-E was a multicenter, single-arm phase II trial enrolling patients with T2–3bN0 rectal adenocarcinoma ≤5 cm from the anal verge. Patients received short-course radiotherapy (25 Gy/5 Fx) followed by four cycles of CAPOX plus toripalimab. Good responders were eligible for watch-and-wait (WW) or local excision (LE), and total mesorectal excision was recommended for poor responders or those with high-risk features after LE. The primary endpoint was complete response (CR), including clinical CR with WW and pathologic CR. Secondary endpoints included OP rate, adverse effects, and quality of life. Results: From December 2022 to March 2024, 33 patients were enrolled, with 75.8% staged as T3. After iTNT, 16 patients achieved clinical CR and adopted WW. Pathologic CR was observed in eight of eight LE and five of nine patients who underwent total mesorectal excision. The most common grade 3 to 4 adverse event was thrombocytopenia (27.3%). After a median follow-up of 24.1 months, four local regrowths and one metastatic recurrence occurred. The total CR rate was 72.7%, and the OP rate was 60.6%. Conclusions: As an exploratory trial, TORCH-E demonstrated a promising iTNT approach achieving a high CR rate, enabling OP through WW and selective LE in early low rectal cancer, warranting subsequent randomized validation.